Aclaris Therapeutics (ACRS) Other Gross PP&E Adjustments (2017 - 2025)
Historic Other Gross PP&E Adjustments for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $5.8 million.
- Aclaris Therapeutics' Other Gross PP&E Adjustments fell 30.97% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year decrease of 30.97%. This contributed to the annual value of -$13.3 million for FY2024, which is 827.02% down from last year.
- Latest data reveals that Aclaris Therapeutics reported Other Gross PP&E Adjustments of $5.8 million as of Q3 2025, which was down 30.97% from $5.9 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Other Gross PP&E Adjustments ranged from a high of $6.3 million in Q3 2023 and a low of -$14.3 million during Q4 2022
- Moreover, its 5-year median value for Other Gross PP&E Adjustments was $5.0 million (2022), whereas its average is $1.5 million.
- As far as peak fluctuations go, Aclaris Therapeutics' Other Gross PP&E Adjustments plummeted by 2684.16% in 2021, and later surged by 2718.35% in 2023.
- Quarter analysis of 5 years shows Aclaris Therapeutics' Other Gross PP&E Adjustments stood at -$13.0 million in 2021, then fell by 9.98% to -$14.3 million in 2022, then grew by 14.16% to -$12.3 million in 2023, then decreased by 8.27% to -$13.3 million in 2024, then soared by 143.61% to $5.8 million in 2025.
- Its Other Gross PP&E Adjustments stands at $5.8 million for Q3 2025, versus $5.9 million for Q2 2025 and $5.9 million for Q1 2025.